First Do No Harm: Medication‐Related Problems Among Patients With Cirrhosis
Lydia Aye, Michael Volk – 1 May 2019
Lydia Aye, Michael Volk – 1 May 2019
Koichiro Ohashi, Zhijun Wang, Yoon Mee Yang, Sandrine Billet, Wei Tu, Michael Pimienta, Suzanne L. Cassel, Stephen J. Pandol, Shelly C. Lu, Fayyaz S. Sutterwala, Neil Bhowmick, Ekihiro Seki – 1 May 2019 – Nonalcoholic fatty liver disease (NAFLD) enhances the growth and recurrence of colorectal cancer (CRC) liver metastasis. With the rising prevalence of NAFLD, a better understanding of the molecular mechanism underlying NAFLD‐associated liver metastasis is crucial. Tumor‐associated macrophages (TAMs) constitute a large portion of the tumor microenvironment that promotes tumor growth.
Marco Spada, Roberta Angelico, Carlo Dionisi‐Vici – 30 April 2019
Silvia Nardelli, Barbara Lattanzi, Manuela Merli, Alessio Farcomeni, Stefania Gioia, Lorenzo Ridola, Oliviero Riggio – 30 April 2019 – Muscle alterations (myosteatosis and sarcopenia) are frequent in cirrhosis and related to some complications including overt hepatic encephalopathy (HE). The aim of our study was to investigate the relationship between muscle alterations and minimal HE (MHE) and their role in the risk of overt HE. Sixty‐four patients with cirrhosis were administered the Psychometric Hepatic Encephalopathy Score and animal naming test to detect MHE.
Raymond J. Lynch, Fei Ye, Quanhu Sheng, Zhiguo Zhao, Seth J. Karp – 30 April 2019
Christopher Kasia, Steven J. Scaglione – 30 April 2019
Shaham Mumtaz, Nathan Schomaker, Natasha Von Roenn – 30 April 2019
Daniel Berger, Vishal Desai, Sujit Janardhan – 30 April 2019